From methadone to LAAM: New therapeutic profiles. Utility of therapeutic monitoring (TM);De la metadona al LAAM: Nuevos perfiles terapéuticos. Utilidad de la monitorización terapéutica (MT)

Adicciones

Volumn 13, Issue 3, 2001, Pages 305-314

  Bano Ma D ^a   Lopez Ma L ^a   Agujetas, M ^a   Munoz V ^a   Guillen J L ^a  

^a Programa Municipal de Drogas   (Spain)

Author keywords

LAAM; Methadone; Methadone plasma levels; New profiles of patients; Pharmacokinetic

Indexed keywords

METHADONE; OPIATE DERIVATIVE;

DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG MONITORING; OPIATE ADDICTION; REVIEW; WITHDRAWAL SYNDROME;

EID: 0034768206     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.566     Document Type: Review

References (76)

1. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
2. Reducing the risk of AIDS through methadone maintenance treatment
3. Resultados del estudio piloto realizado en el Programa Municipal de Drogas de Majadahonda sobre niveles plasmáticos de metadona
4. La nevirapina induce síntomas de abstinencia en pacientes en programa de mantenimiento con metadona con infección VIH
5. Niveles plasmáticos de metadona. Resultados después de 15 meses de seguimiento en el Programa Municipal de Drogas de Majadahonda
6. Practical issues of pharmacotherapy availability and trialing Chapter III
7. Metabolism of acetlymethadol. A sensitive assay for nor-acetylmethadol and the identification of a new active metabolite
8. Evluación de la efectividad de diferente subprogramas de metadona
9. Plasma and urine disposition of 1-alpha-acetylmethadol and its principal metabolites in man
10. The effects of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of metadone
11. Foreword
12. Actions and addiction liabilities of alpha-acetylmethadol in man
13. Use of miotic effect in evaluating analgesic drugs in man
14. A comparison of thwice weekly LAAM and daily methadone in employed heroin addicts
15. Antibodies to morphine and impaired immune reactivity
16. Induction of antibodies to mèthadone during methadone maintenance treatment of heroin addicts and its possible clinical implications
17. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats
18. Methadone maintenance: New research on a controversial treatment
19. And implanted reservoir of morphine solution for rapid induction of physical dependence in rats
20. Técnica analítica para la determinaci6n de niveles plasmáticos de metadona
21. Crime and drug use among applicants for methadone maintenance
22. Methadone withdrawal when starting an antiretroviral regimen including nevirapine
23. Plasma I-alpha-acetylmethadol after acute and chronic administration
24. Subjetive and objective symptoms in relation to plasma methadone concentration in methadone patients
25. The levels of methadone in the plasma in methadone maintenance
26. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain
27. Methadyl acetate vs. methadone: A double-blind study in heroin users
28. Comparison of acetyl methadol and methadone in the treatment of long term heroin users: A pilot study
29. Opioid analgesics and antagonists
30. Drogadicción y abuso de drogas
31. A comparison of levomethadyl acetate, buprnorphine, adn methadone for opioid dependence
32. Disposition of acetylmethadol in relation to pharmacologic action
33. Correlates of drug injection behaviours among methadone outpatients
34. Evaluation of clinic attendance schedules for LAAM and methadone a controlled study
35. Plasma and urine levels of methadone
36. Rifampicin-induced methadone withdrawal
37. Methadone in treatment physiological and pharmacological issues
38. Introduction and background to the feasibility research
39. Levo-alpha-acetylmethadol (LAAM) for opiate addiction
40. Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine
41. American opiate substitution treatment programs: From methadone to LAAM and Buprenorphine
42. The use of plasma levels to optimize methadone maintenance treatment
43. Algoritmo del seguimiento de niveles plasmáticos de metadona en pacientes HIV en tratamiento con nevirapina
44. AHFS Drug Information 90. American Hospital Formulary Serviced
45. The metabolism of I-acetylmethadol in the rat: The identification of the probable active metabolite
46. The effects of mehtadone on immune function among injecting drug users: A review
47. Interacciones medicamentosas de la metadona
48. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alfa-acetylmethadol (LAAM). NLAAM and methadone
49. Levomethadyl approved for treatment of opiate dependence
50. Clinical pharmacokinetics of methadone
51. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert
52. Pharmacokinetic and Pharmacodynamic principles of illicit drug and treatment of illict drug users
53. Levo-alpha-acetylmethadol (LAAM) for the Treatment of Opiate Dependence. A White Paper
54. A 3- year progress report on the implementation of LAAM in the United States
55. Modification of hepatic microsomal oxidative drug metabolism in rats by the opiate maintenance drug acetylmethadol, proposxyphene and methadone
56. Live activities and life quality of heroin addicts in and out of treatment
57. LAAM instead of take-home methadone
58. El LAAM. Nueva alternativa en tratamientos de mantenimiento con sustitutivos". En:Tratamientos sustitutivos en dependencias a opiáceos. Metadona, LAAM, Heroína
59. Methadone/LAAM maintenance: A comparison study
60. High-dose morphine and methadone in cancer patients: Clinical Pharmacokinetic considerations of oral treatmen
61. What is important in drug misuse treatment?
62. The National Institute on Drug Abuese and methadone maintenance treatment
63. Intravenous drug use, methadone and AIDS. Ask not for whom the bell tolls
64. Urinary metabolites of methadone, in maintenance subjects
65. The fate of optical isomers of a- acetylmethadol
66. Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol
67. Phenytoin induced methadone withdrawal
68. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program
69. Intravenous and oral I-alfa-acetymethadol: Pharmacodynamics and Pharmacokinetic in humans
70. Methadone concentrations in plasma and their relationship to drug dosage
71. Steady -state pharmacokinetics of methadone in opioid addicts
72. The pharmacokinetics of Methadone in healthy subjects and opiate users
73. Therapeutic drug monitoring for methadone: Scanning the horizon
74. Valoración y seguimiento de los tratamientos con metadona:indice de retenci6n,marcadores biológicos y comportamentales